Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Frequently asked questions
What sector does Contineum Therapeutics Inc. Class A Common Stock (CTNM) operate in?
Contineum Therapeutics Inc. Class A Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Contineum Therapeutics Inc. Class A Common Stock (CTNM) current stock price?
As of the latest data, Contineum Therapeutics Inc. Class A Common Stock stock price is $14.98, with a previous close of $14.82. Contineum Therapeutics Inc. Class A Common Stock gained $0.16 in the last trading session, representing a 1.08% increase.
What is Contineum Therapeutics Inc. Class A Common Stock (CTNM) current market capitalization?
Contineum Therapeutics Inc. Class A Common Stock market cap is approximately 493.72 million.
What is Contineum Therapeutics Inc. Class A Common Stock (CTNM) Earnings Per Share (EPS)?
The trailing EPS is -$1.65, and the forward EPS is -$1.82.
What is Contineum Therapeutics Inc. Class A Common Stock (CTNM) EBITDA?
Contineum Therapeutics Inc. Class A Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -17.29 million.
Does Contineum Therapeutics Inc. Class A Common Stock (CTNM) pay dividends?
No. Contineum Therapeutics Inc. Class A Common Stock does not pay a dividend.
What is Contineum Therapeutics Inc. Class A Common Stock (CTNM) beta (volatility) score?
Contineum Therapeutics Inc. Class A Common Stock has a beta of 0.741, indicating lower volatility than the overall market.
